Methods and compositions for early cancer detection
AssigneeAccuragen Holdings Limited
InventorsLi WENG, Malek FAHAM, Tobias WITTKOP, Yontao LU, Ling Fung TANG
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and systems for detecting non-metastatic cancer in a subject, comprising measuring a total cfDNA fragment size distribution for the plurality of cfDNA nucleic acid molecules of the subject and comparing the total cfDNA fragment size distribution for the plurality of cfDNA nucleic acid molecules of the subject to the total cfDNA fragment size distribution for the plurality of cfDNA nucleic acid molecules from a healthy control.
Claims28
A method of detecting a non-metastatic cancer in a subject, the method comprising:
- (a) obtaining a sample comprising a plurality of cell-free deoxyribonucleic acid (cfDNA) polynucleotides of the subject;
- (b) using at least a subset of the plurality of cfDNA polynucleotides or derivatives thereof to measure a total cfDNA fragment size distribution for the plurality of cfDNA polynucleotides of the subject;
- (c) computer processing the total cfDNA fragment size distribution for the plurality of cfDNA polynucleotides of the subject with the total cfDNA fragment size distribution for the plurality of cfDNA polynucleotides from a healthy control;
- and
- (d) classifying the subject as having an increased risk of non-metastatic cancer when, based at least in part on a result of (c), the total cfDNA fragment size distribution shows an increase in fragments having sizes of up to 170 bases in the subject as compared to the healthy control.
(canceled)
-19. (canceled)
-100. (canceled)
A method of detecting a non-metastatic cancer in a subject, comprising:
- (a) obtaining a sample comprising a plurality of cell-free deoxyribonucleic acid (cfDNA) nucleic acid molecules of said subject;
- (b) using at least a subset of the plurality of cfDNA polynucleotides or derivatives thereof to measure a total cfDNA fragment size distribution for said plurality of cfDNA nucleic acid molecules;
- and
- (c) determining that said subject has or is at increased risk of having a non-metastatic cancer when, based at least in part on a result of (b),_said total cfDNA fragment size distribution shows an increase in fragments as compared to a total cfDNA fragment size distribution for said plurality of nucleic acid molecules from a healthy control.
Dependencies are inferred from the claim text.